The total clinical experience with biosimilar medicines exceeds 2 billion patient treatment days

Translating experience into regulation 1 August 2022 More than 15 years of experience with biosimilar medicines show…
EMA/HMA share definitive EU-wide position on biosimilar… 19 September 2022 The Biosimilar medicines group, a Medicines for Europe sector group,…
New report assesses progress on biosimilar medicine policies… 29 March 2021 Biosimilar medicines are increasingly relevant to public health as emphasised by the…
Biosimilar medicines have delivered 18BN€ total savings for… 15 December 2021 Open